PTJ
VRTX icon

Paul Tudor Jones’s Vertex Pharmaceuticals VRTX Stock Holding History

Paul Tudor Jones’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Buy
5,400
+3,800
+238% +$1.68M ﹤0.01% 1742
2026
Q1 		$714K Sell
1,600
-10,500
-87% -$4.9M ﹤0.01% 2596
2025
Q4 		$5.49M Sell
12,100
-5,400
-31% -$2.33M 0.01% 1094
2025
Q3 		$6.85M Buy
17,500
+8,100
+86% +$3.39M 0.01% 989
2025
Q2 		$4.18M Buy
+9,400
New +$4.33M 0.01% 1198
2025
Q1 		– Sell
-1,200
Closed -$483K – 3729
2024
Q4 		$483K Buy
+1,200
New +$556K ﹤0.01% 2267

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Paul Tudor Jones's VRTX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 30,176 shares worth $15M. The stake represents 0.02% of the portfolio and ranks #616 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in VRTX as recently as Q4 2025.

Paul Tudor Jones first reported a position in VRTX in Q2 2014 and has held it in 26 quarters since. The position peaked at $20.1M in Q3 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Paul Tudor Jones held 30,176 shares of Vertex Pharmaceuticals worth $15M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Paul Tudor Jones position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.02% of Paul Tudor Jones's portfolio in Q2 2026, its #616 holding.
  • Paul Tudor Jones first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
  • Paul Tudor Jones's Vertex Pharmaceuticals position peaked at $20.1M in Q3 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.